KYTX — Kyverna Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $384.53m
- $213.59m
- 43
- 18
- 98
- 53
Annual cashflow statement for Kyverna Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -26.4 | -28.9 | -60.4 | -127 |
| Depreciation | ||||
| Non-Cash Items | 8.1 | 2.06 | 2.83 | 3.24 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -4.49 | -10.3 | 3.42 | 7.86 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -22.2 | -36.1 | -52.4 | -114 |
| Capital Expenditures | -1.29 | -0.768 | -0.621 | -2.21 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 0 | -13.3 | -8.16 | -159 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -1.29 | -14.1 | -8.79 | -161 |
| Financing Cash Flow Items | — | — | -1.65 | -3.36 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 72.5 | 11.9 | 58.1 | 337 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 49.1 | -38.3 | -3.08 | 62 |